Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298666 | 0.83 | SHBG (0.39) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL3299387 | 0.82 | SHBG (0.53) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL3296635 | 0.78 | GABRA1 (0.44) | HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL3297623 | 0.76 | SHBG (0.38) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL3294314 | 0.73 | SHBG (0.32) | SHBGCYP3A4SMN1; SMN2 | |
| SCHEMBL9638515 | 0.71 | SHBG (0.45) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL11179954 | 0.71 | SHBG (0.45) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL29560219 | 0.71 | SHBG (0.61) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL3303307 | 0.71 | SHBG (0.46) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 | |
| SCHEMBL3297694 | 0.71 | SHBG (0.46) | SHBGCYP3A4SMN1; SMN2HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | SHBG 2999/4885CYP3A4 1577/4885SMN1; SMN2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.